ISR's application to conduct a phase I/II clinical trial of the dry powder nasal vaccine for SARS-CoV-2 in Bangladesh has been approved. The first in human study will be conducted with 150 volunteers at two qualified study sites in Dhaka, Bangladesh. Vaccine and infection naïve volunteers will be randomized to receive 2 vaccine doses or placebo 4 weeks apart.

The study subjects will be monitored for safety and specific T cell and immunoglobulin immune responses.